Benzodiazepine-like substances and hepatic encephalopathy. Implications for treatment

CNS Drugs

Volumn 8, Issue 2, 1997, Pages 91-101

  Cossar, Jill A ^a   Hayes, Peter C ^a   O'Carroll, Ronan E ^b  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF STIRLING   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; BENZODIAZEPINE RECEPTOR INVERSE STIMULATING AGENT; DIAZEPAM; DIAZEPAM BINDING INHIBITOR; FLUMAZENIL; FLUNITRAZEPAM; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; NEUROSTEROID; PENTOBARBITAL; PICROTOXIN; PREGNENOLONE; RADIOLIGAND; RO 14 7437; SARMAZENIL; TERT BUTYLBICYCLOPHOSPHOROTHIOATE;

ANIMAL MODEL; BINDING SITE; CHRONIC LIVER DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG MECHANISM; GABAERGIC TRANSMISSION; HEPATIC ENCEPHALOPATHY; HUMAN; HYPOTHESIS; LIVER FAILURE; MEDICAL RESEARCH; NEUROPSYCHIATRY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030764466     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199708020-00001     Document Type: Review

References (53)

1. Butterworlh RF. Hepatic encephalopathy. In: Arias IM, Boyer JL, Fausto N, et al., editors. The liver: biology and pathobiology. 3rd ed. New York: Raven Press, 1994: 1193-208
2. Butterworth RF, Giguere JF, Michaud J, et al. 'Ammonia'; key factor in the pathogenesis of hepatic encephalopathy. Neurochem Pathol 1987; 6: 1-12
3. Zieve L, Nagasawa HT. Methanethiol and derivatives in hepatic encephalopathy. J Lab Clin Med 1988; 111: 595-7
4. Shafer D, Jones A. Hepatic encephalopathy and the gamma-aminobutyric-acid neurotransmitter system. Lancet 1982; 1: 18-20
5. Kmjevic K, Phillis JW. Iontophoretic studies of neurones in the mammalian cerebral cortex. J Physiol (Lond) 1963; 165: 274-304
6. Smialowski A. The effect of intra-hippocampal administration of gamma amino butyric acid (GABA). In: Fonnum F, editor. Amino acids as chemical transmitters. New York: Plenum Press, 1978: 1977-80
7. Samson Y, Bernan J, Puppata S, et al. Cerebral uptake of benzodiazepine measured by positron emission tomography in hepatic encephalopathy. N Engl J Med 1987; 316: 414-5
8. B binding sites in the cerebral cortex of rats with acute hepatic encephalopathy, Brain Res 1993; 629: 355-7
9. Chiappa KH, Ropper AH. Evoked potentials in clinical medicine. N Engl J Med 1982; 306: 1140-7
10. Skolnick P, Moncada V, Barker JL, et al. Pentobarbital: dual actions to increase brain benzodiazepine receptor affinity. Science 1981; 211: 1448-50
11. Moroni F, Riggio O, Carla V, et al. Hepatic encephalopathy: lack of changes of gamma amino butyric acid content in plasma and cerebrospinal fluid. Hepatology 1987; 7: 816-20
12. Mullen K, Martin J, Mendelson W, et al. Could an endogenous benzodiazepine ligand contribute to hepatic encephalopathy? Lancet 1988; 1: 457-9
13. Basile A, Harrison P, Hughes R, et al. Relationship between plasma benzodiazepine receptor ligand concentrations and severity of hepatic encephalopathy. Hepatology 1994; 1: 112-21
14. Rothstein J. Benzodiazepine-receptor ligands and hepatic encephalopathy: a causul relationship? Hepatology 1994; 19: 248-50
15. A receptor complex in an experimental model of hepatic encephalopathy: evidence for elevated levels of an endogenous benzodiazepine receptor ligand. J Neurochem 1989; 53: 1057-63
16. Basile A, Hughes R, Harrison P, et al. Elevated brain concentrations of 1.4-benzodiazepines in fulminant hepatic failure. N Engl J Med 1991; 7: 473-8
17. Basile A. The contribution of endogenous benzodiazepine re ceptor ligands to the pathogenesis of hepatic encephalopathy. Synapse 1991; 7: 141-50
18. Mullen K, Martin J, Mendelson W, et al. Evidence for the presence of a benzodiazepine receptor binding substance in cerebrospinal fluid of a rabbit model of hepatic encephalopathy. Metab Brain Dis 1989; 4: 253-60
19. Olasmaa M, Rothstein J, Guidotti A, et al. Endogenous benzodiazepine receptor ligands in human and animal hepatic encephalopathy. J Neurochem 1990; 55: 2015-22
20. Mullen K, Szauter K, Kaminsky-Russ K. 'Endogenous' benzodiazepine activity in body fluids of patients with hepatic encephalopathy. Lancet 1990; 336: 81-3
21. Wilder P, Fisch H, Schoch P, et al. Increased benzodiazepine-like activity is neither necessary nor sufficient to explain acute hepatic encephalopathy in the thioacetamide-treated rat. Hepatology 1993; 18: 1459-64
22. A receptor complex in hepatic encephalopathy. Autoradiographic evidence for the presence of elevated levels of a benzodiazepine receptor ligand. Neuropsychopharmacology 1990; 3 (1): 61-71
23. Bakti G, Fisch HU, Kurlaganis G, et al. Mechanism of the excessive sedative response of cirrhotics to benzodiazepines: model experiments with triazolam. Hepatology 1987; 7: 629-38
24. Rossle M, Deckert J, Jones EA. Autoradiographic analysis of GABA-benzodiazepine receptors in an animal model of acute hepatic encephalopathy. Hepatology 1989; 10: 143-7
25. Maddison JE, Dodd PR, Morrison M, et al. Plasma GABA, GABA-like activity and the brain GABA-benzodiazepine receptor complex in rats with chronic hepatic encephalopathy. Hepatology 1987; 7: 621-8
26. A) binding sites and of central benzodiazepine receptors are unchanged in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Hepatology 1988; 8: 1084-8
27. Lavoie J, Pomier-Layrargues G, Butterworth RF. Increased densities of peripheral-type benzodiazepine receptors in brain autopsy samples from cirrhotic patients with hepatic encephalopathy. Hepatology 1990; 11: 874-8
28. Giguere J-F. Hamel E, Butterworth RF. Increased densities of binding sites for the 'peripheral-type benzodiazepine receptor ligand [3H]PK 11195 in rat brain following portacaval anastomosis. Brain Res 1992; 585: 295-8
29. Rothstein J, McKhann G, Guarneri P, et al. Cerehrospinal fluid content of diazepam binding inhibitor in chronic hepatic encephalopathy. Ann Neurol 1989; 26: 57-62
30. van der Rijt C, Knegt R, Schalm S, et al. Flumazenil does not improve hepatic encephalopathy associated with acute ischemic liver failure in the rabbit. Metab Brain Dis 1990; 5: 131-41
31. Bosman D, van den Buijs C, Haan J, et al. The effects of benzodiazepine-receptor antagonists and partial inverse agonists on acute hepatic encephalopathy in the rat. Gastroenterology 1991; 101: 772-81
32. Bassett M, Mullen K, Skolnick P, et al. Amelioration of hepatic encephalopathy by pharmacologic antagonism of the GABA-benzodiazepine receptor complex in a rabbit model of fulminant hepatic failure. Gastroenterology 1987; 93: 1069-76
33. Steindl P, Puspok A, Druml W, et al. Beneficial effect of pharmacological modulation of the GABAa-benzodiazepine receptor on hepatic encephalopathy in the rat: comparison with uremic encephalopathy. Hepatology 1991; 14: 963-8
34. Gammal SH, Basile AS, Geller D, et al. Reversal of the behavioral and electrophysiological abnormalities of an animal model of hepatic encephalopathy by benzodiazepine receptor ligands. Hepatology 1990; 11: 371-8
35. Basile A, Jones A. The involvement of benzodiazepine receptor ligands in hepatic encephalopathy. Hepatology 1994; 20: 541-4
36. Wilder P, Risch HU, Schlaepfer T, et al. Reply [letter]. Hepatology 1994; 20: 543
37. Meier R, Gyr K, Scholer A. Persisting benzodiazepine metabolites responsible for the reaction to the benzodiazepine antagonist flumazenil in patients with hepatic encephalopathy. Gastroenterology 1991; 101: 274-5
38. Puspok A, Herneth A, Steindl P, et al. Hepatic encephalopathy in rats with thioacetamide-induced acute liver failure is not mediated by endogenous benzodiazepines. Gastroenterology 1993; 105: 851-7
39. Basile A, Gammal SH, Mullen KD, et al. Differential responsiveness of cerebellar Purkinje neurons to GABA and benzodiazepine receptor ligands in an animal model of hepatic encephalopathy. J Neurosci 1988; 8: 2414-21
40. Ferenci P, Grimm G, Meryn S, et al. Successful long-term treatment of portal-systemic encephalopathy by the benzodiazepine antagonist flumazenil. Gastroenterology 1989; 96: 240-3
41. Grimm G, Ferenci P, Katzenschlager R, et al. Improvement of hepatic encephalopathy treated with flumazenil. Lancet 1988; 17: 1392-4
42. Bansky G, Meier P, Riederer E, et al. Effects of the benzodiazepine receptor antagonist flumazenil in hepatic encephalopathy in humans. Gastroenterology 1989; 97: 744-50
43. Pomier-Layrargues G, Giguere J, Lavoie J, et al. Flumazenil in cirrhotic patients in hepatic coma: a randomised double-blind placebo-controlled crossover trial. Hepatology 1994; 19: 32-7
44. Butterworth RF, Wells J, Pomier-Layrargues G. Reply [letter]. Hepatology 1995; 21: 605
45. Gyr K, Meier R, Haussler P, et al. Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: a double blind, randomised, placebo controlled multicentre study. Gut 1996; 39: 319-24
46. Masterton G, O'Carroll RE. Psychological assessment in liver disease. Baillieres Clin Gastroenterol 1995; 9: 791-809
47. Gooday R, Hayes PC, Bzeizi K, et al. Benzodiazepine receptor antagonism improves reaction time in latent hepatic encephalopathy. Psychopharmacology 1995; 119: 295-8
48. Tarter RE, Hegedus A, van Thiel DH, et al. Hepatic dysfunction and neuropsychological test performance in alcoholics with cirrhosis. J Stud Alcohol 1986; 46: 74-7
49. Arria AM, Tarter RE, Kabene MA, et al. The role of cirrhosis in memory functioning of alcoholics. Alcohol Clin Exp Res 1991; 15: 932-7
50. Tarter RE, van Thiel DH, Arria AM, et al. Impact of cirrhosis on the neuropsychological test performance of alcoholics. Alcohol Clin Exp Res 1988; 12: 619-21
51. Kapczinski F, Sherman D, Williams R, et al. Differential effects of flumazenil in alcoholics and nonalcoholic cirrhotic patients Psychopharmacology 1995; 120: 220-6
52. Kapczinski F, Curran V, Przemioslo R, et al. Cognitive impairments of alcoholic cirrhotic patients: correlation with endogenous benzodiazepine receptor ligands and increased affinity of platelet receptors. J Neurol Neurosurg Psychiatry 1996; 60: 676-80
53. Michel H, Solere NM, Granier P, et al. Treatment of cirrhotic encephalopathy with L-dopa: a controlled clinical trial. Gastroenterology 1980; 9: 207-11